OSSTEC is a technology company.
OSSTEC has raised $4.0M across 2 funding rounds.
OSSTEC has raised $4.0M in total across 2 funding rounds.
OSSTEC has raised $4.0M in total across 2 funding rounds.
OSSTEC's investors include Elbow Beach Capital.
OSSTEC is a medtech startup developing innovative 3D-printed partial knee implants that combine biomimetic cementless fixation with lattice structures mimicking bone's trabecular properties, aimed at improving patient outcomes in osteoarthritis treatment.[1][2][3] These implants target patients needing knee replacements, addressing issues like bone loss and complications from traditional designs by promoting natural bone ingrowth, enabling outpatient care, and enhancing long-term fixation for active lifestyles.[1][2][4] Serving orthopedic surgeons and patients globally—with a US market launch focus—the company solves key problems in orthopedics, such as revision surgeries and suboptimal implant performance, backed by strong growth including a £2.5M funding round closed in early 2025 to fund regulatory approval, team expansion to nine members, and first revenues.[1][4][5]
OSSTEC was founded in May 2021 by Dr. Maxwell Munford, stemming from his PhD project at Imperial College London's Department of Mechanical Engineering, which explored 3D printing applications in surgery.[2][4] Munford, influenced by a business-oriented upbringing, gained formalized startup training through the MedTech SuperConnector program, propelling the idea forward; he later became an Enterprise Fellow at the Royal Academy of Engineering.[2] Early traction included £800,000 in public funding, preclinical studies in sheep and human cadavers, an oversubscribed £2M (later reported as £1.2M seed plus additional) round in 2023-2024, team growth to eight members, product unveiling, and key events like cadaver labs at HSS New York and conferences (ISTA, AAHKS, AAOS).[1][2][4] Led by surgeons like Chief Medical Officer Alex Liddle and engineers, the company evolved from research to commercialization, supported by Imperial's networks including a San Francisco Venture Trek.[4]
OSSTEC rides the wave of advanced manufacturing in medtech, particularly 3D printing for personalized orthopedics, amid rising global knee replacement demand (1.3M annually) driven by aging populations and osteoarthritis prevalence.[2] Timing aligns with regulatory shifts favoring innovative implants and DeepTech investment surges, as seen in their funding from Imperial-linked VCs and US networking.[4][5] Market forces like high revision rates from bone quality loss favor their bone-mimicking tech, potentially disrupting a field dominated by legacy designs while influencing ecosystems through Imperial spinouts, surgeon adoption, and outpatient trends that cut costs and improve access.[1][2][4]
OSSTEC is poised for US regulatory approval, initial UK surgeries, and first revenues in 2025, scaling via its expanded team and investor backing.[1][4] Trends like AI-optimized 3D printing, value-based care emphasizing durability, and global ortho demand will propel growth, potentially expanding to full knee or other joints. Their surgeon-led model could redefine implant standards, amplifying influence in medtech innovation hubs like Imperial and US markets—empowering more active lives, one step further.[1][2]
OSSTEC has raised $4.0M across 2 funding rounds. Most recently, it raised $3.0M Seed in March 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2025 | $3.0M Seed | Elbow Beach Capital | |
| Mar 1, 2023 | $1.0M Seed | Elbow Beach Capital |